Business

Aradigm Corporation has received a 2-year Small Business Initiative Research (SBIR) grant of about $972,000 from the National Institute of Allergy and Infectious Diseases (NIAID) and National Institutes of Health (NIH) for development of Linhaliq… Read more . . .

According to Verona Pharma’s mid-year update, the company is developing MDI and DPI formulations of its RPL554, an inhaled PDE3/PDE4 inhibitor. Nebulized RPL554 is currently in Phase 2 development, and Verona reported positive results from… Read more . . .

Innovus Pharmaceuticals says that it has ordered 220,000 units of FlutiCare, an OTC fluticasone propionate nasal spray, in preparation for its US launch in the fourth quarter of 2017. The company says that it will… Read more . . .

Endo Pharmaceuticals filed suit against Lupin on July 28, 2017 alleging infringement of patents related to Par’s Nascobal cyanocobalamin nasal spray. The suit was filed in the United States District Court for the Eastern District… Read more . . .

Milestone Pharmaceuticals has raised $55 million in a Series C financing round led by Novo Holdings A/S, the company said. The company plans to use the money to fund Phase 3 clinical development of etripamil,… Read more . . .

Dewmar International says that it has filed a provisional patent application titled “Cannabinoid Formulation to Treat Lung Cancer” with the United States Patent and Trademark Office (USPTO). The companies current brands include “Kush Cakes” psychedelic… Read more . . .

Perrigo announced that it has settled Hatch-Waxman litigation brought by Meda Pharmaceuticals and Cipla regarding Dymista azelastine HCl/fluticasone propionate nasal spray. Meda’s NDA for Dymista was approved by the FDA for the treatment of allergic… Read more . . .

Sunovion has announced that it has agreed to divest US rights to the Alvesco ciclesonide MDI for the treatment of asthma and the Omnaris and Zetonna ciclesonide nasal sprays for the treatment of allergic rhinitis… Read more . . .

During a July 11, 2017 meeting between AstraZeneca CEO Pascal Soriot and Australian Prime Minister Malcolm Turnbull, Soriot announced an A$100 million expansion of the company’s manufacturing facility in Sydney, which he called “really a… Read more . . .